This is a translation of the Swedish press release published 2022-10-20

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

The Board of Directors of Neola Medical AB (publ) (“Neola Medical” or “the Company”) today announces the outcome of the rights issue with preferential rights for the Company’s shareholders (the “Rights Issue”) which was resolved upon by the Board of Directors on 8 September 2022 and approved by an extraordinary general meeting on 27 September 2022. In the Rights Issue, 20,490,992 shares were subscribed for with support of subscription rights, corresponding to approximately 49 percent of the Rights Issue and 111,948 shares, corresponding to approximately 0.3 percent of the Rights Issue, were subscribed for without support of subscription rights. This implies that 13,204,695 shares, corresponding to approximately 31 percent of the Rights Issue, will be allotted to the share issue guarantors, whereby the Rights Issue will be subscribed to a total of approximately 80 percent. This also implies that the Company is provided with a new shareholder in LMK Venture Partners AB, which was the only external share issue guarantor in the Rights Issue. Neola Medical will receive a total of approximately SEK 44 million before transaction costs through the Rights Issue.

“I would like to thank both existing and new shareholders for their confidence in this rights issue. We are very pleased to welcome LMK Venture Partners AB as a new shareholder in Neola Medical and that we have now secured funding that will enable us to continue to develop, validate and commercialize Neola®. We now look forward to preparing for the market launch of Neola® and continuing to create long-term shareholder value”, says Hanna Sjöström, CEO of Neola Medical.

Read the full translation of the Swedish press release here: Press communication – Neola Medical announces outcome of rights issue

Read the press release (in Swedish) here: Press release – Neola Medical offentliggör utfall i företrädesemissionen